![Andrew Hopkinson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Andrew Hopkinson is the founder of NuVision Biotherapies Ltd., where he currently holds the title of Chief Scientific Officer.
He founded the company in 2014.
Actieve functies van Andrew Hopkinson
Bedrijven | Functie | Begin |
---|---|---|
NuVision Biotherapies Ltd.
![]() NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | Oprichter | 01-07-2014 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
NuVision Biotherapies Ltd.
![]() NuVision Biotherapies Ltd. Pharmaceuticals: MajorHealth Technology NuVision Biotherapies Ltd. commercializes biotherapies for treating ‘front of the eye’ disease and trauma. It offers Omnigen, an ‘off the shelf’, transportable biological matrix that can be used as an effective wound dressing for a range of indications including ocular surface indications. The firm also offers Tereo, a process that gently preserves the tissue such that it is stored in a dry state. The company was founded by Andrew Hopkinson in July 2014 and is headquartered in Nottingham, the United Kingdom. | Health Technology |